Tenderwize
Retour à la recherche

Open House Pharmaceutical Rebate Agreements Lamivudine and Dolutegravir, ATC J05AR25

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Apr 03, 2028 · 583 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Lamivudin und Dolutegravir, ATC J05AR25

45/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

45 / 100

Complexité

20 / 100

Facteurs de risque

The open-house model is not subject to procurement law. Legal recourse is through social courts, not procurement review...

No estimated value or volume commitments. The agreement may result in negligible revenue if the drug is not widely pres...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until May 2028
  • Entering into non-exclusive rebate agreements for lamivudine and dolutegravir (ATC J05AR25).
  • Contracts run from June 1, 2026 to May 31, 2028.
Afficher le résumé complet

This is an open-house model for non-exclusive rebate agreements for the active ingredients lamivudine and dolutegravir (ATC J05AR25) by AOK Bayern. It is not a competitive procurement but a voluntary participation model. All eligible pharmaceutical companies can join. No estimated value provided. The contract period is June 1, 2026 to May 31, 2028, with contracts possible at any time until April 3, 2028. Monthly deadlines apply for start dates.

Risques

The open-house model is not subject to procurement law. Legal recourse is through social courts, not procurement review...

No estimated value or volume commitments. The agreement may result in negligible revenue if the drug is not widely pres...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical company.

Administrative

  • Submit a signed and completed contract along with annex 'Festlegung der vertragsgegenständlichen Arzneimittel'.
  • Submit a signed declaration of reliability (Eigenerklärung zur Zuverlässigkeit).

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No award criteria specified; participation is open to all eligible companies.

Acheteur

Localisation

München, DEU

Site web

www.aok.de

Profil acheteur

Ouvrir le profil

Identifiant

DE811695320

Activité

Health

Lots (1)

LOT-0001

Open House Pharmaceutical Rebate Agreements Lamivudine and Dolutegravir, ATC J05AR25

Non-exclusive rebate agreement for lamivudine and dolutegravir. All eligible pharmaceutical companies may join with identical terms. Monthly submission deadlines (3rd of month) for start on the 1st of next month. Final deadline for conclusion is April 3, 2028.

SuppliesFrameworkEU fundedElectronic submission

Localisation

DE212, Germany

Durée

May 2026 - May 2028

Catégorie

Pharmaceutical products

Critères d'attribution

No award criteria specified; participation is open to all eligible companies.

Date limite

Deadline Apr 03, 2028

Détails de la procédure

Date de publication
14 Apr 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
256387-2026

Documents (2)

Document de consultation 1Portail de soumission 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30